Japan’s Ministry of Health, Labor and Welfare has approved biotechnology manufacturer CSL and Arcturus Therapeutics’ new Covid-19 vaccine against the JN.1 strain of the disease. The ministry approved for sale the two companies’ ‘updated self-amplifying mRNA Covid-19 vaccine for protection against JN.1 Strain’, to be distributed in Japan by Meiji Seika Pharma. According to CSL…
Australia’s most successful manufacturer, biotechnology company CSL today reported net profit after tax of $2.64 billion for the 12 months ended 30 June 2024, up 25 percent on a constant currency basis. Net profit after tax (NPATA) was $2.91 billion, up 15 percent on revenue up 11 percent to $14.8 billion. CSL’s Chief Executive Officer…
A partnership involving CSL Seqirus, and which has saved more than 2,000 lives through access to antivenoms in Papua New Guinea since beginning in 2018, has been extended by another three years out until 2027. According to a statement from CSL Seqirus – a division of ASX-listed biotech company CSL – it is an initiative…
Today in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Daniel Splatt and Michelle Tan highlight the benefits of a patent box system, much advocated but missing from our innovation ecosystem. The World Intellectual Property Organisation’s Global Innovation Index has revealed a steady decline in Australia’s knowledge, technology, and creative…
Australia’s R&D effort is focused around medical technologies and here in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Dig Howitt of Cochlear outlines the way ahead to support innovation in the sector. Cochlear has long been a pioneer in innovation. It has reshaped hearing technology and made substantial contributions…
Faltering business expenditure on R&D is a major factor in Australia’s poor innovation performance. Today in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Dr John Howard identifies businesses’ failings. This is an edited excerpt (full paper link below). From 1981 to 1995, Australian businesses made steady progress in lifting…
Biotechnology giant CSL has reported net profit after tax for the six months ended December 31 of $1.9 billion, up 20 percent on the previous corresponding period. Underlying net profit was $2.02, set on revenue up 11 percent to $8.05 billion. CSL CEO and Managing Director Dr Paul McKenzie said: “Our strong first half result…
Biotechnology manufacturer CSL has failed to prove the efficacy of one of its most promising drugs under development – CSL112 (apolipoprotein A-I [human]). As recently as last year the Melbourne company was testing the drug in reducing the risk of follow on adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI) or…
Melbourne biotechnology giant CSL has hit back at doubters posting a massive rise in revenues for the year. The company, which has been questioned by analysts about its recent acquisition of the Vifor pharmaceutical business, reported revenues up 31 percent at constant currency value to $13.31 billion for FY23. Sales for CSL Vifor in the…
What were the five biggest stories of the week? Here’s what visitors to this site were reading. 5) AUKUS technology sharing comes a step closer Australian access to foreign technologies on a range of cutting edge industrial technologies is a step closer following progress in the US Senate to the provision of exemptions from export…
